Goldman Sachs sees UK potential despite weak growth and inflation fears

For Goldman Sachs bankers in London, the useful part of the firm’s latest UK note was not a bullish macro call. It was the reminder that a bad headline can still hide tradeable opportunity.

Goldman Sachs Research said in its June 2 report, Investors May Be Overlooking the UK’s Economic Potential, that the United Kingdom remains weighed down by weak growth, soft productivity gains, persistent inflation and pressure on fiscal policy. But the same note argued that the country still has real medium-term strengths, with AI, life sciences and defence singled out as areas where the UK can still attract capital and support growth.

That is a more awkward message than a simple buy call, and it is exactly the kind of message London teams have to defend internally and in front of clients. The macro backdrop is still messy. The Office for National Statistics said UK real GDP rose 0.6% in the first quarter of 2026 after revised growth of 0.2% in the fourth quarter of 2025, with services doing most of the work. Even so, Goldman’s view stayed cautious because the broader picture still points to fragile productivity and sticky inflation.

The Bank of England reinforced that tension when it held Bank Rate at 3.75% on April 30, 2026, with inflation at 2.8% and the next rate decision due June 18. Goldman’s separate UK outlook, published Jan. 8, had already set a subdued tone for the year, calling for trend-like growth, a further rise in unemployment, materially lower inflation and three more Bank Rate cuts to 3%.

What makes the June 2 note more than macro commentary is the policy and funding backdrop. The UK government has already promised an £86 billion science-and-tech package, while Rachel Reeves has announced an £11 billion increase in defence spending, lifting defence outlays from 2.3% of GDP to 2.6% by 2027. Those are not small signals for sectors Goldman is telling clients to watch.

The numbers in innovation markets help explain why the bank is taking a more nuanced line. NatWest said UK startups raised £17.5 billion across more than 2,000 deals in 2025. Dealroom data showed UK venture investment at £7.8 billion in the first quarter of 2026, with AI startups taking $5.8 billion, or 74% of total UK VC investment. UK biotech venture capital reached £516 million in the same quarter, keeping the country the largest biotech VC market in Europe.

For Goldman employees, the takeaway is practical: the UK should not be treated as a single macro trade or written off as a stagnant market. In London, that means better conversations about risk premia, financing, sponsor coverage and cross-border deals, and more discipline about separating short-term gloom from medium-term upside. That is the kind of contrarian call that can be hard to sell when the headlines are weak, but it is also the sort of research culture that can create real client edge.